Investigators at the National Cancer Institute are enrolling patients with advanced hepatocellular cancers (HCC), in a clinical trial using engineered immune cells, also known as chimeric antigen receptor T-cells or CAR-T cells. In this study, your immune T-cells are collected and modified to target Glypican-3 (GPC3), a protein marker found on the surface of HCC tumors. Researchers hope the altered cells will help identify and fight the cancer cells.
This study involves
- Imaging scans of the chest, abdomen, and pelvis
- A biopsy of your tumor to confirm that it is GPC3 positive
- Leukapheresis - a procedure done to collect white blood cells
- At least a nine-day stay at the NIH Clinical Center
You may be eligible if you
- Are >18 years of age and have a laboratory-confirmed diagnosis of HCC
- Have failed or progressed through prior first line of standard therapy, OR
- Have been intolerant of the standard of care for HCC
- Are not pregnant or planning to become pregnant
There is no cost to participate, and travel assistance may be provided.
The NIH Clinical Center, America's Research Hospital is located on the Metro red line (Medical Center stop).
For more information:
NIH Clinical Center
Office of Patient Recruitment
800-411-1222
TTY users dial 7-1-1
Email: ccopr@nigh.gov
Or go online:
https://go.usa.gov/xtErY
Refer to study # 21-C-0030
Department of Health and Human Services
National Institutes of Health Clinical Center
National Cancer Institute